Informed Choices Increase Survival and Reduce Costs in the Fight Against Cancer

Patients who have received multiple treatments

80 Clinical Trials Options were found
88 Lowered cost to insurance

Patients who have recently diagnosed

20 Clinical Trials Options were found
65 Lowered cost to insurance
The Purpose
Recently, a study was done to compare the effects of implementing Massive Bio’s Virtual Tumor Board – Precision Oncology plan to a group of advanced stage cancer patients with solid tumors.
The Study Group
The patients split into two groups.
  • The first group were patients who had been through multiple treatments and mostly completed tumor profiling.
  • The second group were patients who were recently diagnosed having cancer and they didn’t complete any profiling or treatment.
Both groups were patients with solid tumors at an advanced stage. Each patient has a different tumor type (e.g. breast, lung, etc.).

Group 1- Patients who received multiple treatments

88% cost reduction and 80% referral to clinical trials

Patients received multiple treatments
# of patients recommended for standard therapies
Patients received multiple treatments
# of patients recommended for clinical trials

50% of the patients decided to go to clinical trials identified by Massive Bio

  • The total cost of drugs to insurance companies for 10 patients reduced from $517k to $61k as Massive Bio has identified clinical trials for 80% of the patients. The cost of drugs is absorbed by pharmaceutical companies which drove most of the cost reduction to the insurance.
  • 50% of the patients decided to pursue the clinical trial as Massive Bio was taken patient’s preferences into account prior to trial matching process.
  • For this group, tumor profiling costs were not considered because most of the patients already had their profiling results but they didn’t know how to use the results and integrate into their care plan.

Group 2 - Patients recently diagnosed

65% cost reduction; 76% Progression Free Survival (PFS) increase and 20% referral to clinical trials

Patients received multiple treatments
# of patients recommended for standard therapies
Patients received multiple treatments
# of patients recommended for clinical trials

Total cost of tumor profiling testing and drugs to insurance companies for 10 patients reduced from $687k to $239k and average PFS increased from 3.6 months to 6.3 months. The improvement was primarily due to three factors:

  • Massive Bio eliminated unnecessary testing or usage of large panels with no clear indication of actionability of a given patient.
  • Massive Bio selected FDA approved treatment options with better PFS and less cost.
  • Massive Bio identified clinical trials for 20% of the patients and drug costs were absorbed by pharmaceutical companies.
The Massive Bio Approach
Massive Bio provides an extended team to the treating oncologist and their patients with sub-specialists from large cancer centers. Massive Bio utilizes a state of the art algorithm that takes into account patient’s clinical history, preferences and genetic makeup along with a wealth of scientific research and evidence. This information provides the sub-specialist team a starting point from which they apply their own experiences to compile a report with their recommendations identifying incremental options including: FDA approved therapies, off-label therapies, and clinical trials.

In the end what Massive Bio does, empowering patients, caregivers and treating oncologist, and providing options to make informed choices; eliminating what is not necessary and focus on what is necessary. Massive Bio’s efforts result in increased Progression Free Survival (PFS), reduced cost, and increased number of treatment options that would otherwise not have considered.
X
Talk to Cancer Care Experts:
+1 (844) 627-7246
Top